These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 15308280

  • 1. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
    Lundstrom TS, Sobel JD.
    Infect Dis Clin North Am; 2004 Sep; 18(3):651-68, x. PubMed ID: 15308280
    [Abstract] [Full Text] [Related]

  • 2. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.
    Nailor MD, Sobel JD.
    Infect Dis Clin North Am; 2009 Dec; 23(4):965-82, ix. PubMed ID: 19909893
    [Abstract] [Full Text] [Related]

  • 3. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF, Booker BM, Ogundele AB, Kelchin P.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [Abstract] [Full Text] [Related]

  • 4. Antibiotics for gram-positive bacterial infection: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, telavancin, and ceftaroline.
    Nailor MD, Sobel JD.
    Med Clin North Am; 2011 Jul; 95(4):723-42, vii. PubMed ID: 21679789
    [Abstract] [Full Text] [Related]

  • 5. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
    Abb J.
    Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Quinupristin-dalfopristin and linezolid: evidence and opinion.
    Eliopoulos GM.
    Clin Infect Dis; 2003 Feb 15; 36(4):473-81. PubMed ID: 12567306
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
    Anastasiou DM, Thorne GM, Luperchio SA, Alder JD.
    Int J Antimicrob Agents; 2006 Nov 15; 28(5):385-8. PubMed ID: 17046205
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
    Lundstrom TS, Sobel JD.
    Infect Dis Clin North Am; 2000 Jun 15; 14(2):463-74. PubMed ID: 10829266
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Daptomycin, a lipopeptide antibiotic in clinical practice.
    Weis F, Beiras-Fernandez A, Schelling G.
    Curr Opin Investig Drugs; 2008 Aug 15; 9(8):879-84. PubMed ID: 18666036
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Vancomycin-resistant enterococcal bacteremia pharmacotherapy.
    Patel R, Gallagher JC.
    Ann Pharmacother; 2015 Jan 15; 49(1):69-85. PubMed ID: 25352037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.